33 recruiting in this ClinicalTrials.gov snapshot · reviewed 2026-08-17
AMD trials split dry (including geographic atrophy) versus wet/neovascular disease. Visual-acuity floors, recent anti-VEGF injections, and imaging (OCT) rules are typical. An eye-trial listing is not an appointment with a retina clinic. Sourced from ClinicalTrials.gov. Not a recommendation to join any study.
Each headline is a rewrite of registry fields (phase, intervention, condition). Open the NCT link before you call a site. Eligibility is decided by the study team, not by this page. See how to find a trial and eligibility explained.
Phases in this snapshot: Not a traditional drug phase (9) · Phase 3 (6) · Phase 2 (6) · Phase 1 / Phase 2 (4) · Phase 4 (4) · Phase 1 (3) · Phase 2 / Phase 3 (1)
Intervention hubs that overlap this snapshot: Faricimab · Dapagliflozin
Background: \- Best Vitelliform Dystrophy (Best disease), Late-Onset Retinal Degeneration (L-ORD), and Age-Related Macular Degeneration (AMD) all affect the retina, the light sensing area at the back of the eye. Doctors cannot safely obtain retinal cells to study these diseases.
NCT01432847 · Official ClinicalTrials.gov record · National Eye Institute (NEI)
Background: \- To understand diseases of the retina and the eye, information is needed about people with and without such diseases. Researchers want to study these people and follow them over time.
NCT01496625 · Official ClinicalTrials.gov record · National Eye Institute (NEI)
This study will measure the long-term whether it is safe and how hard side effects are to live with of the Port Delivery System with ranibizumab (PDS) (100 mg/mL) in participants with neovascular age-related macular degeneration (nAMD) who have either completed Phase II Study GX28228 (Ladder), Phase III Study GR40548 (Archway), Phase IIIb Study WR42221 (Velodrome), or completed Week 24 visit in Study WR42221 but were not eligible to be randomly assigned in WR42221.
NCT03683251 · Official ClinicalTrials.gov record · Hoffmann-La Roche
Background: Age-related macular degeneration is a common eye disease in people over 50. The "dry" form of the disease can worsen into geographic atrophy, causing blind spots.
NCT04339764 · Official ClinicalTrials.gov record · National Eye Institute (NEI)
This trial will study the safety and how well it works of intranasal delivery of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cell exosomes for the treatment of non-arteritic ischemic optic neuropathy
NCT05147701 · Official ClinicalTrials.gov record · The Foundation for Orthopaedics and Regenerative Medicine
Age-related macular degeneration (AMD) is a degenerative retinal disease. The prognosis of the exudative form was transformed by the introduction of the anti-VEGF monoclonal antibody treatments ranibizumab \[1\] and aflibercept \[2\] in the 2010s.
NCT06271330 · Official ClinicalTrials.gov record · Nantes University Hospital
This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD).
NCT06541704 · Official ClinicalTrials.gov record · Regeneron Pharmaceuticals
This study wants to assess the long-term whether it is safe and how hard side effects are to live with after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.
NCT06635148 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC
Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina.
NCT06659549 · Official ClinicalTrials.gov record · Galimedix Therapeutics Inc
The goal of this clinical trial is to measure the safety and how well it works of IVB103 injection in subjects with nAMD.
NCT06737354 · Official ClinicalTrials.gov record · InnoVec Biotherapeutics Inc.
We aimed to investigate the success rate of a planned quarterly (every 12-16 weeks) faricimab injection schedule, following a disease inactivity achieved after initial 2-4 loading doses of faricimab, for nAMD to achieve stability without recurrence at a tertiary eye centre.
NCT06742307 · Official ClinicalTrials.gov record · Hospital Authority, Hong Kong
This study wants to measure the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.
NCT06847542 · Official ClinicalTrials.gov record · Hoffmann-La Roche
This is a prospective, randomly assigned study that compares 8-week and 12-week follow-up intervals after the 4 monthly injections in the loading phase. Patients with active CNV confirmed on optical coherence tomography (OCT) and OCT angiography (OCTA) will be randomly assigned into two groups and followed for 44 to 56 weeks.
NCT06875245 · Official ClinicalTrials.gov record · Faculty Hospital Kralovske Vinohrady
1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.
NCT06924021 · Official ClinicalTrials.gov record · University of Wisconsin, Madison
This study aims to investigate the impact of intravitreal injection of anti-vascular endothelial growth factor (anti VEGF) Faricimab on renal function of diabetic patients. Faricimab is a new anti-VEGF drug which inhibits both VEGF-A and Ang-2 and it is used for the treatment of diabetic macular edema and neovascular age related macular degeneration.
NCT06929507 · Official ClinicalTrials.gov record · University Hospital, Alexandroupolis
Neovascular age-related macular degeneration (nAMD), also known as "wet" AMD, is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. this study wants to assess how safe and effective Surabgene Lomparvovec is in treating participants with Neovascular age-related macular degeneration (nAMD).
NCT07007065 · Official ClinicalTrials.gov record · AbbVie
This Phase 3 study is evaluating the safety and how well it works of 4D-150 versus aflibercept in participants with neovascular age-related macular degeneration (nAMD). Enrollment in the primary global cohort has been completed; Study centers in Japan remain open for enrollment for the Japan cohort.
NCT07064759 · Official ClinicalTrials.gov record · 4D Molecular Therapeutics
This study wants to perform a pivotal trial of iPredict, an automated AI-based system for early diagnosis and prediction of late AMD in primary care and ophthalmology settings. Patients will be invited to participate in this study by having non-dilated photos of their eyes taken by an FDA approved fundus camera (DRSPlus from Centervue Inc., CA), at their primary care doctor's office or general ophthalmologist office.
NCT07084883 · Official ClinicalTrials.gov record · iHealthScreen Inc
This is a non-treatment, watch-and-measure (no experimental treatment required) study to provide insights into the short-term progression of GA secondary to AMD in participants aged ≥55 years. This is a multi-center, non-treatment, watch-and-measure (no experimental treatment required) study which aims to identify participants who have progressive GA to allow quantification of structural and functional parameters that characterize the progression of GA, and to see if these correlate with genetic or lifestyle factors.
NCT07144137 · Official ClinicalTrials.gov record · Complement Therapeutics
AMD is a leading cause of blindness in individuals over 50 years old, with dry AMD being the most common form. Geographic atrophy (GA) is an advanced stage of dry AMD characterized by progressive retinal cell degeneration.
NCT07174687 · Official ClinicalTrials.gov record · Washington University School of Medicine
This study will measure the safety, tolerability, pharmacokinetics and preliminary how well it works of Oral HX9428 tablets in patients with wet age-related macular degeneration(wAMD)
NCT07185841 · Official ClinicalTrials.gov record · Fujian Haixi Pharmaceuticals Co., Ltd.
EYE-RES-104 is a randomly assigned, dose-masked study of intravitreal remigromig (EYE103) in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO). The study will consist of 4 patient cohorts, with participants in each cohort randomly assigned (1:1) to either a low dose of remigromig via IVT or a high dose of remigromig via IVT.
NCT07205887 · Official ClinicalTrials.gov record · EyeBiotech Ltd.
This is a sequential Phase 1/2, two-part, multicenter study on safety, tolerability, and how well it works of one-time intravitreal SAR446597 for the treatment of participants with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). The core phase duration will be approximately 2 years for each participant.
NCT07215234 · Official ClinicalTrials.gov record · Sanofi
Neovascular age-related macular degeneration (nAMD), also called wet AMD, can cause serious vision loss. While anti-VEGF (anti Vascular Endothelial Growth Factor) treatments such as ranibizumab help many patients, about 20 40% have a suboptimal response.
NCT07249216 · Official ClinicalTrials.gov record · Singapore National Eye Centre
If the subject who has nAMD voluntarily agrees to participate in this clinical study by signing the informed consent form, screening assessments will be conducted within 4 weeks prior to the first dose of the investigational drug. During the screening visit, the eligibility of the subject will be assessed and one study eye will be selected.
NCT07367282 · Official ClinicalTrials.gov record · Junyeop Lee
Whose aim is to: Determine the percentage of patients with resolution of subretinal hyperreflective material (SHRM) at week 16. This study is intended to be performed in the ophthalmology departments or ophthalmology clinics of the participating sites, located in Spain.
NCT07403825 · Official ClinicalTrials.gov record · Biobizkaia Health Research Institute
Phase I Study of the Safety and Preliminary how well it works of Human induced pluripotent stem cells-derived Retinal Pigment Epithelial Cells (hiPSC-RPEs) Subretinal Transplantation in Adanced (Late-Stage) Age-Related Macular Degeneration(AMD) Patients.
NCT07418177 · Official ClinicalTrials.gov record · The First Affiliated Hospital with Nanjing Medical University
To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
NCT07441642 · Official ClinicalTrials.gov record · Novartis Pharmaceuticals
To measure the how well it works of a personalized treat-and-extend regimen of faricimab for treatment-who have not tried this kind of treatment before polypoidal choroidal vasculopathy
NCT07461441 · Official ClinicalTrials.gov record · Yeungnam University College of Medicine
The goal of this study is to evaluate whether AIV007 provides benefits to patients with neovascular age-related macular degeneration in improving vision and that it has an acceptable safety profile. Participants will receive either a periocular injection of AIV007 or intravitreal injection of Eylea (control arm) to the study eye and return to the clinic monthly for safety and how well it works observations and/or continued treatment.
NCT07557121 · Official ClinicalTrials.gov record · AiViva BioPharma, Inc.
This is a first-in-human Phase 1 study evaluating the whether it is safe and how hard side effects are to live with of C.001 in patients with retinal diseases involving degeneration of the retinal pigment epithelium. Participants will receive a single administration of C.001 delivered by subretinal injection.
NCT07594236 · Official ClinicalTrials.gov record · Cellio Therapeutics Inc
Intravitreal anti-VEGF injections are a mainstay of treatment for retinal diseases such as neovascular age-related macular degeneration, diabetic macular edema and retinal vein occlusion, and usually require repeated administration over years. During each injection an eyelid speculum holds the lids open and the upper eyelid is exposed to repeated mechanical stretch.
NCT07821450 · Official ClinicalTrials.gov record · Abdulkadir Küçük
This study will assess the safety and how well it works of RO7965032 to address a significant unmet medical need in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
NCT07851259 · Official ClinicalTrials.gov record · Genentech, Inc.
This hub lists 33 recruiting Macular degeneration studies from a ClinicalTrials.gov snapshot, rewritten in plain English. Each card links to its NCT record. You can also search the official registry for “age-related macular degeneration” at https://clinicaltrials.gov/search?cond=age-related%20macular%20degeneration.
A phase explainer, a plain-English summary grounded in the brief summary, inclusion/exclusion extracted from the public eligibility block, sponsor name, and any central contact the sponsor published. It is not a match to a trial.
Sites that appear on these records include Barcelona, Spain; Sacramento, California; Austin, Texas; Dallas, Texas; London, United Kingdom. A city on a record is not a guarantee that the site is taking new patients this week — call the NCT contact.
No. Eligibility is decided by the study team using the protocol, labs, and consent. Our “who it is for” list is a readable extract of public inclusion text only.